TRIAL DETAIL

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Drug:	Imatinib
Trial Name:	STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
NCT#:	NCT00006357
Conditions:	Gastrointestinal Stromal Tumor; Ovarian Cancer; Sarcoma; Small Intestine Cancer
Status:	Completed
Phase:	2	Start Date 08/01/2000	Age of Trial (yrs) 24.3
Treatment Phase:	First-line
Drug Category:	KIT/PDGFRA inhibitor
Strategy:	Block KIT
Trial Type:	Specifically GIST plus other cancers
Other Protocol IDs:	CDR0000068226, EORTC-62001, EORTC-16003, NOVARTIS-CSTI5710203
Sponsor:	EORTC
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:	Oral
Trial Notes:

Trial Links

Trial Results

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor.

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.

Drug Information

All About Gleevec (LRG website)

Gleevec prescribing information

Patient assistance program (insurance, financial help, etc).

Gleevec blood level monitoring (LRG story/info)

Gleevec drug interactions (LRG site)

Gleevec.com website (GIST portion)

FDA approves adjuvant Gleevec

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment

European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients

Disintegration of chemotherapy tablets (including imatinib) for oral administration in patients with swallowing difficulties

Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.

Trial Sites

Name	Address	City	State	Zip	Country